First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors - Concepedia

Concepedia

Publication | Open Access

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

DOI Full Paper Access

23

Citations

56

References

2024

Year

Martin Wermke, Tobias A.W. Holderried, Jason J. Luke, Van K. Morris, Winfried Alsdorf, Katrin Wetzko, Börje S. Andersson, Ignacio I. Wistuba, Edwin R. Parra, M. Belal Hossain,

Journal for ImmunoTherapy of Cancer

Abstract

NCT04639245, NCT05430555.

References

	Year	Citations

Page 1